IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, pa… Read more
IOL Chemicals and Pharmaceuticals Limited (IOLCP) - Net Assets
Latest net assets as of September 2025: ₹17.51 Billion INR
Based on the latest financial reports, IOL Chemicals and Pharmaceuticals Limited (IOLCP) has net assets worth ₹17.51 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹24.13 Billion) and total liabilities (₹6.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹17.51 Billion |
| % of Total Assets | 72.58% |
| Annual Growth Rate | 28.9% |
| 5-Year Change | 33.9% |
| 10-Year Change | 795.12% |
| Growth Volatility | 43.99 |
IOL Chemicals and Pharmaceuticals Limited - Net Assets Trend (2005–2025)
This chart illustrates how IOL Chemicals and Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IOL Chemicals and Pharmaceuticals Limited (2005–2025)
The table below shows the annual net assets of IOL Chemicals and Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹16.88 Billion | +4.73% |
| 2024-03-31 | ₹16.12 Billion | +6.88% |
| 2023-03-31 | ₹15.08 Billion | +8.29% |
| 2022-03-31 | ₹13.92 Billion | +10.46% |
| 2021-03-31 | ₹12.60 Billion | +54.93% |
| 2020-03-31 | ₹8.14 Billion | +71.51% |
| 2019-03-31 | ₹4.74 Billion | +119.87% |
| 2018-03-31 | ₹2.16 Billion | +14.33% |
| 2017-03-31 | ₹1.89 Billion | +0.09% |
| 2016-03-31 | ₹1.89 Billion | -9.01% |
| 2015-03-31 | ₹2.07 Billion | -0.98% |
| 2014-03-31 | ₹2.09 Billion | +20.96% |
| 2013-03-31 | ₹1.73 Billion | -0.35% |
| 2012-03-31 | ₹1.74 Billion | +0.73% |
| 2011-03-31 | ₹1.72 Billion | +16.32% |
| 2010-03-31 | ₹1.48 Billion | +18.01% |
| 2009-03-31 | ₹1.26 Billion | +47.86% |
| 2008-03-31 | ₹849.06 Million | +157.05% |
| 2007-03-31 | ₹330.31 Million | +78.06% |
| 2006-03-31 | ₹185.50 Million | +76.29% |
| 2005-03-31 | ₹105.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IOL Chemicals and Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1405651660600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹14.02 Billion | 83.08% |
| Common Stock | ₹587.10 Million | 3.48% |
| Other Comprehensive Income | ₹11.60 Million | 0.07% |
| Other Components | ₹2.26 Billion | 13.37% |
| Total Equity | ₹16.88 Billion | 100.00% |
IOL Chemicals and Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of IOL Chemicals and Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aminex PLC
PINK:AEXFF
|
$77.17 Million |
|
Genovate Biotechnology Co Ltd
TWO:4130
|
$77.18 Million |
|
Arbor Technology
TWO:3594
|
$77.24 Million |
|
Kintor Pharmaceutical Limited
PINK:KNTPF
|
$77.25 Million |
|
Ballard Mining Ltd
AU:BM1
|
$77.14 Million |
|
Gajah Tunggal Tbk
JK:GJTL
|
$77.13 Million |
|
ÖKOWORLD AG
XETRA:VVV3
|
$77.11 Million |
|
mPLUS Corp
KQ:259630
|
$77.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IOL Chemicals and Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,115,100,000 to 16,876,600,000, a change of 761,500,000 (4.7%).
- Net income of 1,010,700,000 contributed positively to equity growth.
- Dividend payments of 234,800,000 reduced retained earnings.
- Other comprehensive income decreased equity by 14,400,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹1.01 Billion | +5.99% |
| Dividends Paid | ₹234.80 Million | -1.39% |
| Other Comprehensive Income | ₹-14.40 Million | -0.09% |
| Total Change | ₹- | 4.73% |
Book Value vs Market Value Analysis
This analysis compares IOL Chemicals and Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26.09x to 5.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹2.61 | ₹68.21 | x |
| 2006-03-31 | ₹3.93 | ₹68.21 | x |
| 2007-03-31 | ₹8.03 | ₹68.21 | x |
| 2008-03-31 | ₹10.43 | ₹68.21 | x |
| 2009-03-31 | ₹15.56 | ₹68.21 | x |
| 2010-03-31 | ₹13.84 | ₹68.21 | x |
| 2011-03-31 | ₹14.06 | ₹68.21 | x |
| 2012-03-31 | ₹13.37 | ₹68.21 | x |
| 2013-03-31 | ₹13.25 | ₹68.21 | x |
| 2014-03-31 | ₹15.37 | ₹68.21 | x |
| 2015-03-31 | ₹10.34 | ₹68.21 | x |
| 2016-03-31 | ₹7.03 | ₹68.21 | x |
| 2017-03-31 | ₹6.71 | ₹68.21 | x |
| 2018-03-31 | ₹7.68 | ₹68.21 | x |
| 2019-03-31 | ₹16.88 | ₹68.21 | x |
| 2020-03-31 | ₹28.54 | ₹68.21 | x |
| 2021-03-31 | ₹43.22 | ₹68.21 | x |
| 2022-03-31 | ₹47.44 | ₹68.21 | x |
| 2023-03-31 | ₹51.37 | ₹68.21 | x |
| 2024-03-31 | ₹54.90 | ₹68.21 | x |
| 2025-03-31 | ₹11.49 | ₹68.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IOL Chemicals and Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.89%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.41x
- Recent ROE (5.99%) is below the historical average (13.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 53.33% | 6.72% | 1.39x | 5.71x | ₹45.60 Million |
| 2006 | 39.12% | 4.78% | 1.60x | 5.10x | ₹54.02 Million |
| 2007 | 22.86% | 3.73% | 1.15x | 5.35x | ₹42.48 Million |
| 2008 | 14.56% | 3.91% | 1.31x | 2.84x | ₹38.73 Million |
| 2009 | 10.11% | 4.21% | 0.72x | 3.34x | ₹1.40 Million |
| 2010 | 6.76% | 2.87% | 0.69x | 3.43x | ₹-48.00 Million |
| 2011 | 3.59% | 1.59% | 0.64x | 3.54x | ₹-110.55 Million |
| 2012 | 2.74% | 1.01% | 0.69x | 3.96x | ₹-126.07 Million |
| 2013 | 0.92% | 0.33% | 0.66x | 4.20x | ₹-157.11 Million |
| 2014 | 1.58% | 0.59% | 0.76x | 3.54x | ₹-176.26 Million |
| 2015 | -32.17% | -17.32% | 0.55x | 3.39x | ₹-873.71 Million |
| 2016 | -21.62% | -6.90% | 0.75x | 4.19x | ₹-585.39 Million |
| 2017 | 2.47% | 0.67% | 0.86x | 4.33x | ₹-142.00 Million |
| 2018 | 12.84% | 2.88% | 1.13x | 3.95x | ₹61.26 Million |
| 2019 | 49.90% | 14.04% | 1.79x | 1.99x | ₹1.89 Billion |
| 2020 | 44.41% | 19.07% | 1.62x | 1.44x | ₹2.80 Billion |
| 2021 | 35.27% | 22.84% | 1.21x | 1.28x | ₹3.19 Billion |
| 2022 | 12.04% | 7.68% | 1.11x | 1.41x | ₹284.22 Million |
| 2023 | 9.23% | 6.32% | 1.09x | 1.34x | ₹-116.32 Million |
| 2024 | 8.34% | 6.34% | 0.94x | 1.39x | ₹-267.21 Million |
| 2025 | 5.99% | 4.89% | 0.87x | 1.41x | ₹-676.96 Million |
Industry Comparison
This section compares IOL Chemicals and Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IOL Chemicals and Pharmaceuticals Limited (IOLCP) | ₹17.51 Billion | 53.33% | 0.38x | $77.14 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |